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The human type 1 insulin-like growth factor receptor (IGF-1R) is a homodimeric, disulphide-linked (αβ)2 receptortyrosine kinase implicated in normal human growth and
development1. Aberrant IGF-1R signalling is implicated in cancer
proliferation and metastasis2 and IGF-1R has undergone exten-
sive investigation as an anti-cancer target3. IGF-1R is closely
related to the human insulin receptor (IR): their ectodomains
share 53% sequence identity, their respective monomers can form
functional heterodimers and both receptors can bind all three
ligands within the family (insulin and the two insulin-like growth
factors, IGF-I and IGF-II), albeit with varying affinities4. The
bioavailability, activity and tissue distribution of the IGFs are
controlled by a suite of six insulin-like growth factor binding
proteins5, as well as (in the case of IGF-II) by the type 2 insulin-
like growth factor receptor/cation-independent mannose-6-
phosphate receptor6, a receptor unrelated to IGF-1R.
Whereas no three-dimensional structures exist of the intact
IGF-1R ectodomain, two IR-based crystal structures provide
insight into how IGFs might bind to IGF-1R. The first is that of
apo IRΔβ, an IR ectodomain-only construct that lacks a short,
glycosylated segment near the receptor β-chain N terminus which
is deemed superfluous to function7,8. IRΔβ is Λ-shaped (Fig. 1a),
with the first leucine-rich repeat domain (L1), the cysteine-rich
domain (CR) and second leucine-rich domain (L2) of each
receptor monomer being juxtaposed against a linear arrangement
of the first, second and third type III fibronectin domains of the
opposing αβ monomer (FnIII-1΄, -2΄ and -3΄; the ΄ symbol
denoting here and below entities from the alternate monomer).
The insert domain (ID; an ~110-residue region within FnIII-2
and which contains the α/β cleavage site) lies predominantly
within the interior of the Λ-shaped assembly. The C-terminal
region of the α-chain component of ID΄ contains a segment
(αCT΄) that assembles as an α helix on the central β sheet (L1-β2)
of domain L1—together, these elements form site 1, the primary
ligand-binding site9. The degree of sequence identity of IGF-1R
and IR suggests that the IGF-1R ectodomain has a similar three-
dimensional structure to that of IR. The second structure is that
of insulin co-complexed with an isolated IR L1-CR module and
exogenous αCT peptide (Fig. 1b)10,11; the latter receptor elements
minimally reconstitute site 112 and are together termed the
insulin “microreceptor” (μIR)11. This structure reveals that both
insulin and αCT undergo substantial conformational change
upon site 1 engagement. Again, it is reasonable to assume, given
the structural relationship between the ligands13, that the IGFs
bind the primary binding site of IGF-1R in a fashion similar to
that of insulin to μIR14. Indeed, mutagenesis of IGFs reveals a
high degree of correspondence of their respective receptor-
binding surfaces to those of insulin15,16.
Little is known about how either IGFs or insulin interact with
the secondary binding site (site 2) of their cognate receptor, an
event deemed essential for receptor activation17. The current
kinetic model of ligand binding to IGF-1R and IR assumes that
the apo receptor is in an “open” conformation with all four
















































Fig. 1 Structural biology of apo IRΔβ and insulin-bound μIR and the current model of ligand binding kinetics. a The Λ-shaped assembly of IRΔβ (PDB entry
4ZXB)8. Domain colours are L1 light blue, CR red, L2 orange, FnIII-1 green, FnIII-2 yellow, FnIII-3 dark blue, ID light magenta, αCT magenta. The foreground
monomer is in ribbon representation, the background monomer in surface representation (apart from the ID element); dashed lines indicate disordered
residues within the respective ID segments. b Human insulin (A chain grey, B chain black) bound to μIR (PDB entry 4OGA)11, coloured as in a. c Major
pathway of ligand binding to IR and IGF-1R within the current kinetic model. S1, S2: site 1 and site 2 on one receptor monomer; S1΄, S2΄: site 1 and site 2 on
the opposing receptor monomer. Red filled circle: ligand (i.e., IGF-I, IGF-II or insulin). d Steric overlap (asterisked) between insulin and the opposing
fibronectin domain module of the structures depicted in a and b based on overlay of their common domain L1. αCT΄ is shown in both its apo conformation
(thin magenta ribbon) and its insulin-complexed conformation (magenta ribbon) in order to illustrate its altered disposition upon insulin binding
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Incoming ligand engages first with site 1, and then forms a cross-
link to site 2΄, located on the alternate monomer to that which
contributes domain L1 to site 1 (Fig. 1c), with the resultant cross-
link being of high affinity18. An immediate conundrum is that
overlay of the above two IR−based structures indicates that
insulin is sterically prevented from forming a site 1 complex with
apo IRΔβ without displacement of the receptor L1-CR module
away from domains FnIII-1΄ and FnIII-2΄ (Fig. 1d), i.e., the apo
receptor structure is in a “closed” conformation. Resolution then
requires either that (i) ligand binding itself separates domain L1
from the opposing FnIII΄ domain module, (ii) ligand binds to
only a dynamically transient population of receptor conforma-
tions that already have these domains displaced from each other
(i.e., “open” receptors) or (iii) the apo-IRΔβ structure does not
reflect the ectodomain structure within apo holo-receptor. Bio-
chemical and biophysical analyses of IGF-1R indicate that the
separation of domain L1 from the opposing FnIII΄ domain
modules is in fact integral to IGF-1R activation19. These analyses
suggest further that, in the ligand-free state, the receptor trans-
membrane domains are held apart by the Λ-shaped assembly of
the ectodomain, but ligand-induced separation of domain L1
from the FnIII΄ domain module then releases the conformational
constraint on the latter, allowing the attached transmembrane
(TM) helices to interact and autophosphorylation to occur19.
Equivalent data do not exist for IR; however, there is indication
that for IR, receptor activation may instead involve the separation
(rather than coming together) of the transmembrane helices
within the homodimer20.
To address these issues and gain understanding of the
mechanism of ligand binding, we have determined crystal
structures of apo- and IGF-1-bound forms of IGF-1RΔβ, the
latter intriguingly obtained via crystal soaking. IGF-1RΔβ, like
IRΔβ, is an ectodomain-only construct that lacks the likely dis-
ordered and non-functional segment near the N terminus of the
receptor β chain21. These structures, refined using data to reso-
lution of 3.0 Å and 3.27 Å, respectively, were both obtained as co-
complexes with an antibody variable-domain module (Fv). Not
only do our structures provide a wealth of atomic detail regarding
IGF-1R and its interaction with IGF-I, but they also lead to new
insights into the receptor activation mechanism, relevant to those
seeking to design novel agents targeting IGF-1R and/or IR.
Results
Characterization of IGF-1RΔβ. Labelled-ligand competition
binding assays show that IGF-I and IGF-II bind IGF-1RΔβ with
half-maximal inhibitory concentration (IC50) values of 0.14 nM
(0.12–0.17 nM) and 0.33 nM (0.23–0.48 nM), respectively, with
the values in parentheses being the 95% confidence intervals
(Supplementary Figure 1). These values align closely with those
reported for IGFs (0.41 ± 0.1 nM and 0.88 ± 0.6 nM, respectively)
22 in similar assays of an isolated IGF-1R ectodomain devoid of
the “Δβ” modification, demonstrating that the modification does
not affect ligand affinity.
Structure of IGF-1RΔβ + Fv 24-60. The structure of the IGF-1R
ectodomain was obtained by X-ray diffraction analysis of a crystal
of IGF-1RΔβ in complex with the Fv module of the monoclonal
antibody (mAb) 24–6023, the latter employed here as a crystal-
lization chaperone24. The crystal used displayed diffraction to a
maximum resolution of ~3.0 Å (albeit anisotropically; see Meth-
ods and Table 1). Within the crystallographic unit cell, the IGF-
1RΔβ homodimer has twofold crystallographic symmetry and
structure solution was by molecular replacement, employing as
search objects the L1-CR and L2 fragments of IGF-1R (from the
structure of the isolated L1-CR-L2 fragment of the receptor25)
and homology models of Fv 24–60 and of IGF-1RΔβ FnIII-1,-2
and -3, the latter three based on their counterparts within IRΔβ9.
The structure was refined using all data to a resolution of 3.0 Å;
statistics are in Table 1 and representative difference electron
density in Fig. 2a.
The quaternary structure of IGF-1RΔβ (Fig. 3a) exhibits the
same folded-over conformation as IRΔβ, with the locations of
secondary structural elements and domain boundaries being
closely similar to those of IRΔβ. No electron density is seen for ID
residues 642–690; these residues contain the inter-monomer
disulphide bond motif at Cys669-Cys670-Ala-671-Cys672. Elec-
tron density is also poorly defined for residues 509–516 within
domain FnIII-1, this loop contains the inter-monomer disulphide
bond at residue Cys514. The equivalent disulphide bond regions
are also poorly defined in the structure of IRΔβ. In contrast,
electron density for the α-chain to β-chain disulphide bond
(linking Cys633 to Cys849) is well defined. N-linked glycan
residues could be modelled convincingly at sites Asn21, Asn105,
Asn504, Asn577, Asn610 and Asn883. Of the remaining potential
N-linked sites within IGF-1RΔβ, electron density features were
seen extending from the respective side chains of Asn214,
Asn284, Asn387, Asn408, Asn870 and (possibly) Asn592, but
these were left unmodelled due to lack of adequate order. Some
electron density was present in the vicinity of the side chain of
Asn72—it is unknown whether this site is glycosylated in IGF-1R,
though mass spectrometry has revealed that its counterpart
Table 1 X-ray diffraction data collection and refinement
statisticsa
apo IGF-1RΔβ + Fv
24–60 (PDB 5U8R)
IGF-1RΔβ + Fv
24–60 + IGF-I (PDB
5U8Q)
Data collection
Space group P21212 P21212
Cell dimensions
a, b, c (Å) 95.03, 201.73, 117.75 88.69, 197.66, 117.65




Rmerge 0.25 (3.47) 0.19 (2.07)
I / σ(I) 8.3 (0.6) 9.1 (0.9)
CC1/2 0.999 (0.551) 0.998 (0.775)
Completeness (%) 99.7 (99.5) 98.6 (92.5)
Redundancy 8.9 (7.2) 7.2 (6.7)
B11, B22, B33 (Å2)c 115.2, 117.6, 62.4 157.3, 128.4 71.8
Refinement
Resolution (Å) 46.36–3.00 22.18–3.27











Bond lengths (Å) 0.002 0.002
Bond angles (°) 0.48 0.52
a Each data set was collected from a single crystal
b Values in parentheses are for highest-resolution shell. The resolution limit was set at being the
maximum at which the CC1/2 statistic43 remained significant at the P= 0.001 level of
significance
c Maximum likelihood estimate of overall Bcart, calculated using XTRIAGE within the PHENIX
suite49
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(Asn78) in IR is devoid of glycosylation26. The disposition of the
αCT΄ helix (residues 684–697) upon the surface of domain L1 is
also closely similar to that within the structures of apo IRΔβ9 and
apo μIR27. The resolution of the current structure was sufficient
to avoid ambiguities in the strand register within domains FnIII-1
and FnIII-2, an issue which bedevilled the original structure
determination of IRΔβ8. We note further that, within the crystal
lattice, substantial solvent volume exists in the vicinity of the first
modelled residue (Glu744) of the β chain of IGF-1RΔβ, indicating
that the observed structure is not in conflict with that which could
be adopted by the intact IGF-1R ectodomain (i.e., one devoid of
the “Δβ” mutation/deletion).
The crystallization chaperone, Fv 24–60, is seen attached to
domain CR, consistent with the epitope reported for its parent
mAb23. Further detail of its epitope is provided below. Inspection
of the unit cell reveals that Fv 24–60 mediates the majority of
lattice contacts, consistent with its use to overcome the hindrance
to crystallization posed by the N-linked glycans. The mAb 24–60
is reported to reduce by 90% the affinity of IGF-I binding to a
cell-bound receptor and to a lesser degree the affinity of binding
to a soluble receptor23. Here, the Fv module does not interact
sterically with any receptor components beyond its epitope,
suggesting that relative disposition of domains with the
ectodomain has not been modulated by Fv attachment per se
(see below for further discussion of the likely cause of ligand
affinity reduction).
Despite the above similarities, two salient differences emerge
between the structures of IGF-1RΔβ and IRΔβ. First, the sites of
membrane entry (i.e., the respective C termini of domains FnIII-3
and FnIII-3΄) are substantially closer together in IGF-1RΔβ
(~67 Å) than in IRΔβ (~115 Å), i.e., the overall shape of
IGF-1RΔβ is more “closed” (Fig. 3a) than that of IRΔβ (Fig. 1a).
The altered spacing reflects cumulative differences in the relative
orientations of consecutive domains within the receptor mono-
mers, with the largest being a 26° difference between the two
receptors in the relative orientation of the L1-CR module with
respect to its downstream domain L2 (Fig. 3b). These intra-
monomer differences in domain orientation accumulate to
provide a 17° difference between the two receptors in the
alignment of domain L1 of one monomer with respect to domain
FnIII-2΄ of the adjacent monomer (Fig. 3c).
The second difference lies in the IGF-1RΔβ αCT΄ residues
698–704, which are located C terminal to the αCT΄ helix (residues
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Fig. 2 Stereo view of representative σA-weighted (2Fo−Fc) difference electron density. a The σA-weighted (2Fo−Fc) difference electron density in the
vicinity of IGF-1RΔβ L1 domain residues 28–34 within the crystal of apo IGF-1RΔβ + Fv 24–60. The density is sharpened (Bsharp=−60 Å2) and displayed at
a contour level of 1.7 σ (σ= root-mean-square deviation of the sharpened map). Density is shown only for volume within 2.0 Å of the atoms displayed.
b The σA-weighted (2Fo−Fc) difference electron density in the vicinity of IGF-1RΔβ αCT residues 700–704 within the crystal of apo IGF-1RΔβ + Fv 24–60.
The density is sharpened (Bsharp=−60Å2) and displayed at a contour level of 0.33 σ (σ= root-mean-square deviation of the sharpened map). Density is
shown only for volume within 2.5 Å of the atoms displayed. c σA-weighted (2Fo−Fc) difference electron density in the vicinity of IGF-I residues 11–18 within
the crystal of the IGF-I-complexed IGF-1RΔβ + Fv 24–60. The density is sharpened (Bsharp=−60Å2) and displayed at a contour level of 1.7 σ (where σ is
the root-mean-square deviation of the sharpened map). Density is shown only for volume within 2.0 Å of the atoms displayed
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against the surface of the adjacent domain FnIII-2΄ (Fig. 4a, b). In
contrast, in the structure of apo IRΔβ, the αCT΄ segment is
entirely disordered C terminal to His710 (=IGF-1RΔβ His697),
with the axis of the IR αCT΄ helix (residues 694–710) being
directed away from IR domain FnIII-2΄ (Fig. 4c). This difference
correlates with the differing alignments in the two receptors of
domain L1 with respect to the cognate and adjacent domain
FnIII-2΄ (Fig. 3c).
Of particular interest is the detail of the interface between
domain L1 and domain FnIII-2΄ within the homodimer, as
separation of these domains is implicated in receptor activation19.
Here, the observed interface is sparse (Fig. 4d), burying only
~896 Å2 of molecular surface from solvent and with low shape
correlation (Sc= 0.47)28. The nature of the interface thus appears
consistent with one that is capable of in vivo disassembly. Part of
the interface includes residues from the N-terminal segment
(denoted IDN΄) of the ID΄ as they fold beneath domain L1.
Change in solvent accessibility of this segment upon ligand
binding has been detected in hydrogen/deuterium exchange
experiments29.
Structure of IGF-1RΔβ + Fv 24–60 + IGF-I. Crystals of the
complex of IGF-I with the Fv-bound IGF-1RΔβ were obtained by
soaking IGF-I directly into crystals of the receptor ectodomain/Fv
complex. Incorporation by soaking of IGF-I into the apo crystals
is remarkable, and is presumably facilitated by the crystal’s high
solvent content (~75%). Soaking resulted in altered unit cell
dimensions (Δa=−6.3 Å, Δb=−2.3 Å, Δc=−0.3 Å) without
change in space group. We are not aware of any other instance
where such a large moiety as IGF-I (molecular weight= 7.7 kDa)
has been incorporated into crystals by soaking. Despite cracking,
only limited loss of diffraction resolution occurred (compared to
the resolution typical in our hands of the parent crystals), but
anisotropy persisted. Diffraction data were processed to 3.27 Å
resolution (Table 1). The structure was solved by molecular
replacement, using the domains of the apo IGF-1RΔβ + Fv
24–60 structure as search objects (see Methods). Difference maps
revealed IGF-I bound to the single site 1 within the asymmetric
unit, in a fashion effectively identical to that seen in liganded-μIR
structures10,27, allowing its ready incorporation into the atomic
model. Refinement statistics are in Table 1 and representative
difference electron density in Fig. 2c.
Analysis of the structure reveals that IGF-I binding is
accompanied by a separation of the IGF-1-bound L1-CR module
away from domain FnIII-2΄ (Fig. 5a, b), this displacement being
effected largely by a “hinge” motion close to the junction between
domains CR and L2 (Fig. 5c). Conformational variation at this
junction has been seen across extant structures of the IR
ectodomain and its fragments7,10,30. The site-1-bound IGF-I also
interacts with domain FnIII-2΄, the interface involving residues
Ile583, Ser788, Asn789 and Phe790 of the receptor and residues
Asp53, Leu54 and Arg55 of IGF-I. This interface is remarkably
sparse (Fig. 5d) and hence, in our judgement, does not likely
reflect the site 2 interaction—indeed, of the IGF-I residues
involved in its formation, only Leu54 is deemed on the basis of
alanine scanning mutagenesis15,16 to engage site 2. Whereas at
physiological concentrations of ligand, only one IGF molecule is
anticipated to be bound to the cell-surface expressed receptor18,
the presence here of two IGF-I molecules within the homodimer
is likely a consequence of the supra-physiological concentration
of IGF-I soaking and its subsequent binding within the crystal.
N-linked glycan could be convincingly modelled at sites Asn21,
Asn105, Asn504, Ans577, Asn870 and Asn883, with weaker
density suggestive of carbohydrate (and left unmodelled) seen
extending from the side chains of sites Asn214, Asn284, Asn408,
Asn592 and Asn610. No indication of glycan was apparent at site
Asn72. None of the N-linked glycan (modelled or otherwise)
appeared to be in the immediate vicinity of the bound IGF-I.
Again, substantial solvent volume is apparent in the vicinity of
the first modelled residue (Tyr745) of the β chain of IGF-1RΔβ,
indicating that the observed structure is not in conflict with that
which could be adopted by an intact IGF-1R ectodomain devoid
of the Δβ modification.
The mode of engagement of IGF-I with site 1. Conformational
changes are seen in both the αCT΄ helix and IGF-I upon IGF-I
binding to site 1 of IGF-1RΔβ. These changes largely mimic those
seen in the structure of IGF-I bound to the IR L1-CR+IGF-1R
αCT hybrid-microreceptor complex27 and in the structure of
insulin bound to the μIR10,11. In particular, they include remo-
delling of the αCT΄ helix on the L1-β2 surface and a folding out of
the C-terminal region of the B domain of IGF-I away from the
hormone core in order to allow its engagement by key residues
within the αCT΄ helix.
Details are as follows. In the apo IGF-1RΔβ structure, the αCT΄
helix spans residues 684–696 and engages (via the side chains of
residues Tyr688, Phe692 and Phe695) a hydrophobic trough
formed by the side chains of residues Leu32, Leu56, Phe58,
Phe82, Tyr83, Val88 and Phe90 on the surface of L1-β2 (Fig. 6a).
A potential salt bridge occurs between the side chains of αCT΄
residue Glu685 and L1 residue Arg112. Residues 681–683 are in
an extended conformation N terminal to the αCT΄ helix, while C
terminal to the helix, residues 697–704 order on the surface of the
adjacent FnIII-2΄ domain (see above). Upon IGF-I binding, αCT΄
remodels, its helix now spanning residues 688–701, i.e., αCT΄
unwinds by one turn at its N-terminal end and extends by one
turn at its C-terminal end (Fig. 6b). Concomitantly, the helix re-


















Fig. 3 The crystal structure of apo IGF-1RΔβ. a The Π-shaped assembly of
IGF-1RΔβ. Domain colours are L1 light blue, CR red, L2 orange, FnIII-1 green,
FnIII-2 yellow, FnIII-3 dark blue, ID light magenta, αCT magenta. The
foreground monomer is in ribbon representation, the background monomer
in atomic sphere representation (apart from the ID element); dashed lines
indicate disordered residues within the respective ID segments. b L1-CR-L2
module of IGF-1RΔβ (coloured as in a) overlaid onto that of IRΔβ (black) on
the basis of corresponding residues within the L2 domain, showing the 26°
difference in relative orientation of L1-CR and L2 in the two receptors. c L1/
FnIII-2΄ pair of IGF-1RΔβ (coloured light blue and yellow, respectively)
overlaid onto that of IRΔβ (black) on the basis of corresponding residues
within domain FnIII-2΄, showing the 17° difference in relative orientation of
L1 and FnIII-2΄ in the two receptors
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03219-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:821 | DOI: 10.1038/s41467-018-03219-7 | www.nature.com/naturecommunications 5
L1-β2 strands and to engage the hydrophobic L1-β2 surface via
the side chains of residues Phe692, Phe695, Leu696, Ile700 and
Phe701 (Fig. 6b).
IGF-I, upon engagement with IGF-1RΔβ site 1, is also seen to
undergo a conformational change similar to that seen in the
hybrid microreceptor complex of IGF-I with IR L1-CR + IGF-1R
αCT (and analogously in the microreceptor complex of insulin
with IR L1-CR + IR αCT). IGF-I residues Tyr24 and Phe25 are
displaced from the core of the growth factor, with the side chain
of IGF-1R αCT΄ residue Phe701 now locating into volume
originally occupied by the side chain of IGF-I Phe25 (Fig. 6c). The
side chain of IGF-I Phe23 undergoes rotameric re-arrangement to
bury in a largely hydrophobic pocket formed by the side chains of
domain L1 residues Asn11, Leu33, αCT΄ residue Phe701 and IGF-
I residues Leu14, Gln15 and Cys18 (Fig. 6c), as well as by the
main chain atoms of IGF-I residue Tyr60. The side chain of IGF-I
residue Tyr24 interacts with the side chains of αCT΄ residues
Val702 and Arg704 and with that of IGF-I residue Asn26. The
side chain of IGF-I residue Phe25 stacks against those of domain
L1 residues Asp8 and Arg10 and αCT΄ residue Val702. (Fig. 6c).
No interpretable electron density is apparent for IGF-I B-domain
residues 27–30 nor C-domain residues 31–38, the only C-domain
residues in interpretable density thus being residues Pro39, Gln40
and Thr41. Of these latter residues, only Gln40 interacts here with
the receptor, via αCT΄ residues Phe695 and Ser699 (Fig. 6d). The
absence of density for IGF-I residues 27–38 is important, as
Tyr31, Arg36 and Arg37 have been shown by site-directed
mutagenesis to be critical contacts for high-affinity IGF-I binding
(reviewed in Denley et al.31). In particular, grafting the IGF-I C
domain into the insulin molecule raises the affinity of insulin for
IGF-1R to 19–28% of that of IGF-I32. The absence here of a
visible interaction between elements of the C domain and IGF-1R
may be caused by the attachment of Fv 24–60 (see below). While
the absence of density for the IGF-I C domain does not formally
resolve the issue as to whether or not the αCT peptide “threads”
through the loop formed by the C domain and the helical core of
IGF-I27, residual electron density between IGF-I residues 26 and
39 in the vicinity of IGF-1R domain CR suggests that such
threading occurs. Contacts between IGF-I and the site 1 elements
of the receptor are summarized in Supplementary Table 1. Also
included in Supplementary Table 1 are literature-derived data
regarding the effect of mutations on IGF-I binding to IGF-1R—
these data indicate that many of the site-1-engaging residues of
IGF-I are critical to the interaction. In particular, IGF-I residue
Val44 (Fig. 6d) is a critical site 1 contact; mutation of this residue
to (the larger) methionine causes dwarfism31. Mutation to (the
larger) leucine at the equivalent ValA3 position in insulin
Wakayama causes diabetes33.
Inhibitory nature of mAb 24–60. The mAb 24–60 has been
shown to inhibit IGF-I (but not IGF-II) binding to IGF-1R by up
to 90%22,23. The Fv 24–60 epitope is seen here to comprise pri-
marily the residue 254–265 loop of domain CR (Fig. 7a). This
loop contains a number of acidic residues implicated in IGF
affinity and selectivity, potentially through interaction with basic
residues within the C domain of IGFs30,34,35. The residue
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Fig. 4 Configuration of αCT΄ and domains L1 and FnIII-2΄ of apo IGF-1RΔβ. a Ordering of the C-terminal region of the apo IGF-1RΔβ αCT΄ segment upon the
surface of the adjacent domain FnIII-2΄. Inset below is a sequence alignment of residues at the C terminus of the respective α chains of IGF-1RΔβ and IRΔβ;
residues in green are disordered in the crystal structure of the IRΔβ8. Note that the αCT segment of IRΔβ is that of the A isoform of the receptor7. b
Association of the αCT΄ segment with domains L1 and FnIII-2΄ within the crystal structure of apo IGF-1RΔβ. c Association of the αCT΄ segment with domain
L1 alone within the crystal structure of apo IRΔβ. Green dashed line represents the disordered C-terminal region of the α΄ chain of IRΔβ. The view direction
in b and c is equivalent with respect to the domain L1. d Interaction between domains L1 and FnIII-2΄ within apo IGF-1RΔβ
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structures presented here, but its location differs significantly
from that in the isolated (and Fv-free) L1-CR-L2 fragment of
IGF-1R25, being displaced here towards the volume that must
implicitly be occupied by the (disordered) C domain of IGF-I
(Fig. 7b). We hypothesize therefore that the inhibitory nature of
mAb 24–60 arises allosterically from steric interference of the
displaced 254–265 loop with the C domain of the IGF-I. Sup-
porting this contention is the fact that mAb 24–60 does not affect
IGF-II binding to IGF-1R22—the salient difference between IGF-
II and IGF-I is the four-residue shorter C domain of IGF-II. To
test this hypothesis, we determined, using isothermal titration
calorimetry (ITC; Supplementary Figure 2), the affinity of (a)
IGF-I for IGF-1RΔβ: Kd= 39 ± 8 nM (n= 4), (b) IGF-I for IGF-
1RΔβ pre-complexed with Fv 24–60: Kd= 2.4 ± 0.5 μM (n= 2)
and (c) IGF-I CII (an IGF-I chimera that contains the shorter C-
domain of IGF-II36) for IGF-1RΔβ pre-complexed with Fv 24–60:
Kd= 32 ± 8 nM (n= 2), i.e., replacement of the IGF-I C domain
by that of IGF-II abrogates inhibition by Fv 24–60. These data are
consistent with the inhibitory nature of mAb 24–60 with respect
to IGF-I binding arising from a compromising interaction
between the antibody-conjugated receptor and the C domain of
IGF-I. We note that the Kd value for IGF-I binding to IGF-1RΔβ
is lower (i.e., numerically greater) than the IC50 value reported in
the competition binding assay mentioned above; this difference is
likely associated with the much higher receptor concentration in
the ITC measurements. ITC-derived Kd values for IGF-1R have
not been reported prior in the literature.
Mutational analysis of residues within FnIII-2΄. Our structures
suggest that a number of residues within domain FnIII-2΄ may
play a role in receptor functioning. These residues include (a)
His774, which interacts with αCT΄ residue Phe701 within the apo
ectodomain structure (Fig. 4d), (b) Ser788, Asn789 and Phe790,
which interact with IGF-I within the ligand-complexed ectodo-
main structure (Fig. 5d), and (c) Phe792, which, together with
Phe790, interacts with domain L1 within the apo ectodomain
structure (Fig. 4d). To investigate the role of these five residues,
we transiently transfected IGF-1R knockout fibroblasts (R- cells)
with individual plasmids encoding IGF-1R genes each carrying
alanine mutation at one of the five above sites. The double-
alanine mutant Phe790Ala/Phe792Ala was also tested. All con-
structs led to the expression of mutant IGF-1R (Supplementary
Figures 3a, 3b and 4), apart from the Phe790Ala/Phe792Ala
mutant, which was poorly expressed compared to the wild-type
receptor and thus not considered further. None of the five mutant
receptors expressed displayed an affinity for IGF-I significantly
different from that of wild-type receptor (Supplementary Table 2
and Supplementary Figure 3c). The lack of difference in affinity of
these mutants for IGF-I with respect to that of the wild-type
receptor supports our above assessment that the interaction of
Ser788, Asn789 and Phe790 with IGF-I observed in the soaked
crystals is likely non-physiological (Fig. 4d). The relative activa-
tion of the mutant cells by IGF-I was also determined by mea-
suring the relative degree of phosphorylation of the mutant IGF-
1R residues Tyr1158, Tyr1162 and Tyr1163. There was no dif-
ference in the basal activation of all IGF-1R mutants and, upon
IGF-I stimulation, the Ser788Ala, Asn789Ala and Phe792Ala
mutants were activated to the same level as wild-type IGF-1R
(Supplementary Figures 3b, 3d and 4). These data suggest that
these residues are not significantly involved in ligand binding (in
the case of Ser788 and Asn789) or in stabilizing the association
between L1 and FnIII-2΄ (in the case of Phe792). Interestingly,
His774Ala and Phe790Ala mutant receptors did not respond as
well to IGF-I stimulation as the wild-type IGF-1R (Supplemen-
tary Figures 3b, 3d and 4). His774 appears to play a role in
stabilizing the interaction of the αCT΄ C-terminal segment with
domain FnIII-2΄ and Phe790 in stabilizing the interaction of
domain L1 with domain FnIII-2΄ interaction in the apo receptor
(Fig. 4d), suggesting in turn that these structural motifs may play
a role in ligand-mediated receptor activation.
Discussion
The structures presented here provide three-dimensional views of
the IGF-1R ectodomain homodimer in apo and liganded form.
The apo structure demonstrates that the IGF-1R apo ectodomain
is similar in three-dimensional structure to that of IR, aligning
with the ability of the respective receptor monomers to form
functional hybrid receptors37. The source of the differing dis-
tances in IGF-1RΔβ and IRΔβ of their β-chain C termini is
unclear: it may simply be a consequence of flexibility at the inter-
domain boundaries of one or both receptors and their packing
into different respective crystal lattices. However, if IGF-1R and
IR do have a different mode of activation (i.e., intra-homodimer
TM domain interaction19 vs intra-homodimer TM domain
separation20), then the disparate distances apart of the TM
domains of these two receptors may be associated with these
differing modes. Likewise, the functional implications (if any) of
the disparate arrangement of the C-terminal residues of the αCT΄
segment is unknown. We speculate that it may reflect a difference
in the way the respective αCT΄ segments engage ligand: in the
case of IGFs, the αCT΄ segment likely “threads” through the loop
formed by the IGF C domain and the growth factor core, whereas



































Fig. 5 Mode of IGF-I binding to IGF-1RΔβ. a Bridge formed by IGF-I (black)
between the site 1 components L1 and αCT΄ and FnIII-2΄, showing
separation (asterisked) of the L1-CR module away from FnIII-2΄ and IDN΄. b
Overlay of one “leg” of the IGF-1RΔβ homodimer in its IGF-1-bound form
(coloured ribbon) onto the corresponding domains of the apo IGF-1RΔβ
homodimer (white ribbon). Alignment is based on domains FnIII-2΄ and
FnIII-3΄. c Overlay (via L2) of the L1-CR-L2 module of IGF-1-bound IGF-1RΔβ
(coloured ribbon) onto that of apo IGF-1RΔβ (white ribbon). Pro297, the
hinge point, is in black and asterisked. d Interaction between the site-1-
bound IGF-I (A domain black, B domain white) and FnIII-2΄
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03219-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:821 | DOI: 10.1038/s41467-018-03219-7 | www.nature.com/naturecommunications 7
engagement of the two-chain insulin molecule. Nevertheless, the
IGF-1 complexed structure demonstrates that the mode of IGF-I
engagement with the site 1 components (i.e., domain L1 and
αCT΄) of the receptor is closely similar to that of insulin’s
engagement with the corresponding components of IR10,11, again
aligning with the ability of the receptors to bind each other’s
ligand(s)37.
Together, the structures demonstrate that IGF-I binding obli-
gates a separation of IGF-1R domain L1 away from the FnIII
domain module of the adjacent monomer19. The manner in
which this has occurred within the apo crystals raises the inter-
esting issue as to what extent it reflects binding in vivo. The fact
that binding can occur within the crystal suggests that the ligand
binding process is one of induced fit that results not only in
conformational change in the ligand and the receptor site 1 ele-
ments, but also in the concomitant separation of domain L1 from
the adjacent FnIII΄ domains. Such induced fit must by its nature
involve initial (likely metastable) engagement of the IGF-1 with
structural elements of the receptor ligand binding cavity, the
latter being in the form visualized in the apo receptor structure.
The existence of such a ligand/receptor pre-complex that, upon
relaxation, directs the receptor into an “open” conformation has
not been considered prior in the literature. It is thus opportune to
ask whether such binding is compatible with the extant kinetic
data for the receptor. IGF-1R and IR exhibit complex kinetics,
characterized by a curvilinear Scatchard plot and negative coop-
erativity. The latter is best exemplified by the accelerated dis-
sociation of a pre-bound tracer (e.g., I125-labelled ligand) in the
presence of unlabelled (“cold”) ligand under conditions of “infi-
nite” dilution that preclude tracer rebinding38. These observations
can be explained by the so-called harmonic oscillator (HO)
model18, which assumes that the apo receptor exists in a con-
tinuum of energetic states that can be modelled as arising from
harmonic oscillation of the receptor domains. The majority
(~95%) of these conformations, under physiological conditions,
are postulated to be “open”, i.e., all four sites (1, 1΄, 2 and 2΄) are
exposed to incoming ligand (Fig. 1c). Within the HO model,
conformational oscillation of the open receptor results either (i)
in the presence of ligand, a ligand cross-link to site 2΄ (Fig. 1c), or






















































































Fig. 6 Dissection of the interaction of IGF-I with binding site 1 of IGF-1R. a Conformation of L1-β2 (light blue) and αCT΄ (magenta) in the apo IGF-1RΔβ
structure, compared with b, its conformation in the IGF-I liganded IGF-1RΔβ structure. c Interaction between B domain of IGF-I (black) and the IGF-1R site 1
elements of L1-β2 (light blue) and αCT΄ (magenta). The A domain of IGF-I (located in the foreground) is omitted for clarity. d Interaction between A domain
of IGF-I (black) and the IGF-1R site 1 element αCT΄ (magenta); no interaction is observed between the A domain and L1-β2 (light blue). The IGF-I B domain
is in white
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However, while the HO model provides an accurate fit to the
kinetic data, it cannot readily be mapped to the structures of apo
IGF-1RΔβ or apo IRΔβ, as in these structures, sites 1 and 1΄ (and
possibly also sites 2 and 2΄) are partly occluded from the
incoming ligand (Fig. 1d). Two resolutions are proposed. The first
is to assume that in vivo the receptor oscillations are such that
95% of receptor conformations are “closed” (i.e., inactive), with
the incoming ligand being able to access site 1 only within the 5%
of receptor conformations that are “open” (i.e., the inverse con-
formation percentages to those in the HO model). The second
resolution is that physiological ligand binding occurs by a process
similar to that observed in the crystal, i.e., that ligand binds to the
“closed” receptor by a process of induced fit that concomitantly
results in separation of domains L1 and FnIII-2΄. These models
are not mutually exclusive and both may occur under physiolo-
gical conditions. We note that regardless of the mode of binding,
no more than one mole equivalent of ligand is expected to bind to
the receptor (αβ)2 homodimer at physiological ligand con-
centrations, given that both IGF-1R and IR display negative
cooperativity.
However, the induced fit mechanism requires reformulation of
the kinetic model. We have thus tested whether such reformu-
lation agrees with the receptor binding and negative cooperativity
data (see Methods). Inclusion of a doubly liganded, symmetrical
receptor conformation under appropriate experimental condi-
tions allows substantial simplification of the ligand binding
scheme compared to that of the HO model (Fig. 8a, with detailed
description provided in the Methods section). If rate constants are
chosen to reflect a high-affinity site for ligand of Kd ≈ 0.2 nM and
a low-affinity site of Kd ≈ 6 nM (i.e., approximately those values
derived from the HO model analysis), with insulin having an
additional binding site with a Kd ≈ 1000 nM, then simulation with
these values is seen to yield good agreement with the experi-
mental negative cooperativity data for both receptors (Fig. 8b).
We note that if physiological IGF-I binding to IGF-1R is
indeed by a process of induced fit, then a corollary is that certain
IGF-I residues may interact only transiently with receptor, i.e.,
during formation of the pre-complex, and it thus cannot be ruled
out that some (even all) of the IGF-I residues currently under-
stood to interact with site 2΄ (i.e., IGF-I residues Glu9, Asp12,
Phe16, Leu54 and Glu58)15 may fall into this category. Such
interactions would enhance the ligand on-rate to site 1 and
contribute to high affinity.
In summary, our structure provides the first view of IGF-I in
complex with site 1 of its receptor and the serendipitous way in
which it was obtained by in situ crystal soaking has led us to
propose a previously unconsidered mechanism of receptor acti-
vation. While the HO model remains a valid and general con-
ceptual model (and was indeed the first concerted allosteric
model able to incorporate negative cooperativity arising from
ligand-stabilized asymmetry and bivalent cross-linking), its
mathematical formalism has here been adapted and mapped onto
the structural detail that has emerged for IGF-1R and for IR. The
next challenge in the structural biology of this receptor family will
be to understand the pathway by which the final ligand complex
is formed and how it enables the intricate conformational change
that directs the receptor to its final, activated state.
Methods
Expression and purification of IGF-1RΔβ. A CHO Lec8 cell line stably expressing
IGF-1RΔβ (a construct of the human IGF-1R ectodomain comprising residues
1–905 but with the highly glycosylated segment (residues 718–741) near the N
terminus of the β chain replaced by the quadruplet AGNN) was originally obtained
from CSIRO (Parkville, Australia) by the corresponding author’s laboratory21. Cells
were thawed into Dulbecco's modified Eagle's medium F12 + GlutaMAX medium
(Life Technologies) containing 10 μg mL−1 puromycin (Life Technologies) plus
10% fetal bovine serum (Life Technologies) and expanded by passaging several
times in T150 tissue culture flasks at 37 °C/5% CO2. Cells from the T150 flasks were
then used to seed 850 cm2 roller bottles (Corning, Sigma-Aldrich); these were
grown at 37 °C for 21 days but in the absence of CO2.
IGF-1RΔβ was recovered from harvested media by IGF-I affinity
chromatography on a column of immobilized LONG-R3-IGF-I (GroPep
Bioreagents; Australia) and then further purified by size-exclusion chromatography
(SEC) as follows: the LONG-R3-IGF-1 affinity column was prepared by covalently
binding 40 mg of media grade LONG-R3-IGF-I (GroPep Bioreagents; Australia) to
50 mL Mini-Leak Medium Agarose (Kem-En-Tec; Denmark) as per the
manufacturer’s instructions. Typically, 10 L conditioned medium containing IGF-
1RΔβ was pumped through a 50 mL column of Sepharose CL-4B (Sigma-Aldrich)
to remove non-specifically binding material and then a 50 mL affinity column at 4 °
C, followed by extensive column washing to remove unbound protein. Both
columns were equilibrated with Tris-buffered saline (25 mM Tris-HCl, 137 mM
NaCl, 2.7 mM KCl, pH 8.0) containing 0.02% sodium azide (TBSA). The affinity
column was eluted with 0.4 M NaCl, 0.2 M tri-sodium citrate adjusted to pH 5.0

























Fig. 7 Interaction of Fv 24–60 with IGF-1RΔβ. a Interaction of residues of domain CR of IGF-1RΔβ (red) with Fv 24–60 (variable heavy chain domain pink;
variable light chain domain light grey). b Displacement by Fv 24–60 of the peptide loop formed by IGF-1RΔβ CR residues 254–265 towards the IGF-I
binding site. The yellow ribbon is that of IGF-1R domain CR within the crystal structure of the isolated L1-CR-L2 fragment of IGF-1R obtained in the absence
of attached Fv (PDB entry 1IGR25), overlaid onto that of the IGF-I-bound IGF-1RΔβ structure (red) on the basis of common domain L1. Red sphere: IGF-I
Asn26; blue sphere: IGF-I Pro39. The connecting IGF-I domain C residues 27–38 (indicated putatively by a blue dashed line) are disordered
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Tris-HCl buffer, pH 8.5, to immediately adjust the pH to about 8 and 0.1 mM
phenylmethylsulfonyl fluoride was added. Eluate was concentrated by stirred-cell
ultrafiltration on a 30 kDa cut-off membrane (Amicon) and further purified by
SEC on a Superdex S200 26/60 column (GE Healthcare Lifesciences) equilibrated
with TBSA.
IGF competition binding assay. The integrity of the IGF-1RΔβ protein product
was confirmed by measuring its affinity for IGF-I and IGF-II (GroPep Bioreagents;
Australia) within a europium-labelled IGF-I competition binding assay (Supple-
mentary Figure 1)22,36. Wells of microtiter plates (Greiner Lumitrac 600) were
coated with anti-IGF-1R monoclonal antibody 24–3123 (a gift from Professor K.
Siddle) employing 250 ng per well in bicarbonate buffer, pH 9.2, and blocked with
0.5% bovine serum albumin in 20 mM Tris pH 7.4, 150 mM NaCl, and 0.1% (v/v)
Tween-20 (TBST) for 2 h at room temperature. Purified IGF-1RΔβ (0.5 μg per well
in TBST) or lysates of cells expressing IGF-1R mutants (100 µl) were added to each
well and incubated overnight at 4 °C.
Receptor-grade human IGF-I (GroPep Bioreagents, Australia) was europium
labelled as per the manufacturer’s instructions (DELFIA Europium-labelling kit;
Perkin Elmer). Briefly, 0.43 mM IGF-I was incubated with 2 mM labelling reagent
in a 30 μl reaction (0.1 M Na2CO3, pH 8.5) at 4 °C for 2 days. The reaction was
terminated with 0.05M Tris-HCl, 0.15 M NaCl (pH 7.5), and unbound europium
was removed by Superdex 75 SEC (Amersham Pharmacia Biotech; Sweden) in the
termination buffer. Approximately 3 × 106 fluorescent counts of europium-labelled
IGF-I were added to each well along with increasing concentrations of unlabelled
IGF-I or IGF-II (GroPep Bioreagents; Australia) in a final volume of 100 μl and
incubated for 16 h at 4 °C. Wells were washed four times with TBST, followed by
the addition of 100 µl per well DELFIA enhancement solution (PerkinElmer Life
Sciences). After 10 min, time-resolved fluorescence was measured using 340 nm
excitation and 612 nm emission filters with a Victor X4 2030 Multilabel Plate
Reader (Perkin Elmer). Nine technical replicates were performed for the IGF-I
binding assay and six for the IGF-II binding assay. IC50 values were calculated by
curve fitting with a one-site competition model using Prism 7.0 (GraphPad, USA).
Expression and purification of Fv 24–60. The sequences of the variable heavy
and variable light chain components of the mAb 24–6023 were determined under
contract (Genscript) from amplified mRNA extracted from the hybridoma cell line
(a gift of Professor K. Siddle, University of Cambridge). Synthetic DNA encoding a
single-chain (sc) version of Fv 24–60 was inserted between the KpnI and XhoI sites
of the vector pgpHFT39, an in-house modified version of the vector pTriEx2
(Novagen; EMD Millipore), with the single-chain Fv sequence comprising residues
1–118 of the mAb heavy chain, followed by a linker segment of sequence
ENLYFQGGGGGGGGGGGENLYFQG (i.e., a 10-glycine spacer flanked by two
TEV protease motifs), followed in turn by residues 1–107 of the mAb light chain.
DNA encoding SUMO fusion protein followed by a TEV protease motif was
further included at the N terminus of that encoding the scFv in order to boost yield
in Sf21 cells40. The pgpHFT-SUMO-scFv was then co-transfected with FlashBAC
(Oxford Expression Technologies) into Sf21 insect cells as per the supplier’s
manual. The seed virus was amplified to obtain high-titre viral stocks, which were
then used to infect Sf21 cells grown in insect-XPRESS medium (Lonza). The
protein product was purified from Sf21 cell culture supernatant by Q-Sepharose
(GE Healthcare Lifesciences) anion-exchange chromatography (buffer A: 10 mM
Tris, pH 8.0; buffer B: buffer A + 1.0 M NaCl) and digested with in-house-
produced TEV protease to remove the SUMO domain and the single-chain linker
domain. The desired Fv 24–60 product was then purified from the TEV-digested
sample by MonoQ (GE Healthcare Lifesciences) anion-exchange chromatography
(buffer A: 10 mM Tris, pH 8.0; buffer B: buffer A + 1.0 M NaCl) followed by
Superdex 75 SEC in 20 mM Tris pH 8.0, 160 mM NaCl.
Isothermal titration calorimetry. ITC experiments were performed using a
MicroCal iTC200 instrument (Malvern Instruments) with the cell held at 25 °C and
analysis undertaken with the manufacturer’s software within Origin (version 7.0;
OriginLab).
For the titration of IGF-I against IGF-1RΔβ (n= 4 technical replicates) and of
IGF-I against IGF-1RΔβ + Fv 24–60 (n= 2 technical replicates), IGF-I (GroPep
Bioreagents; Australia) was prepared at concentrations of 80–100 μM (depending
on the replicate) in TBSA. IGF-1RΔβ and IGF-1Δβ + Fv 24–60 prepared separately
in TBSA at concentrations of 7–14 μM (depending on the replicate). The total
number of injections in each titration was 16 at 180 s intervals, with the first
injection being 1 μl and subsequent injections being 2.54 μl.
IGF-I CII was synthesized recombinantly as previously described36. Briefly,
IGF-I CII was expressed in Escherichia coli in inclusion bodies, which were washed
and solubilized in 8M urea containing 40 mM glycine, 0.1 M Tris and 16 mM
dithiothreitol (pH 2.0). Inclusion bodies were desalted on a Superdex 75 column
(GE Healthcare Lifesciences) using the same buffer but with 1.6 mM dithiothreitol.
Fractions containing the IGF-II fusion protein were pooled prior to folding in 2.5
M urea, 12.5 mM glycine, 0.7 M Tris, 5 mM EDTA, 0.5 mM dithiothreitol, 1 mM 2-
hydroxyethyl disulphide, pH 9.1, and dilution to less than 0.1 mgmL−1. The fusion
partner was removed by hydroxylamine cleavage (2 M urea, 1 M hydroxylamine,
0.1 M Tris pH 8.65, 37 °C, 22 h) and a final reverse-phase high-performance liquid
chromatography clean-up. Purified protein was analysed by mass spectroscopy and
N-terminal sequencing and was shown to have the correct mass and to be >95%
pure. For ITC, IGF-I CII was prepared at concentrations of 50–65 μM (depending
on the replicate) in TBSA and the solution then injected into separate volumes of
IGF-1RΔβ + Fv 24–60 prepared at a concentration of 4.5 μM in TBSA (n= 2). The
total number of injections in each titration was 11 at 180 s intervals, with the first
injection being 1 μl and subsequent injections being 3.75 μl.
In all of the above titrations, technical replicates of individual experiments that
employed identical concentrations were performed using the same sample. Errors
for reported mean Kd values are the standard errors of the mean.
Crystallization and data collection. The IGF-1RΔβ + Fv 24–60 complex was
prepared by incubating IGF-1RΔβ with an excess of Fv 24–60 followed by SEC.
Fractions containing the desired product were then concentrated to ~8 mgmL−1 in
10 mM HEPES, pH 7.5. Initial sparse-matrix crystallization screening was con-
ducted in 96-well sitting-drop vapour diffusion format at the Collaborative Crys-
tallization Centre (CSIRO, Parkville, Australia). The crystallization conditions were
then refined in-house to 1.2 M (NH4)2SO4+0.1 M imidazole-malate, pH 7.0. For
diffraction data collection, crystals were transferred to a cryo-protectant solution
comprised of 1.2 M (NH4)2SO4+0.1 M imidazole-malate + 32% sucrose and then
flash-frozen by cryo-plunging directly into a liquid nitrogen bath. All X-ray dif-
fraction data were collected on the Australian Synchrotron beamline MX241 at 100
K (λ= 0.9537 Å). Crystals containing IGF-1RΔβ + Fv 24–60 + IGF-I were
obtained by soaking crystals of IGF-1RΔβ + Fv 24–60 in a solution identical to that
of the mother liquor of crystallization but supplemented with increasing con-
centrations of IGF-I (up to ~1 mgmL−1). Cryo-protection and X-ray data collec-

















































Fig. 8 Induced fit binding of ligand to IGF-1R and IR. a Proposed kinetic scheme. S1, S2: site 1 and site 2 on one receptor monomer; S1΄, S2΄: site 1 and site 2
on the opposing receptor monomer. Black filled circle: hot ligand (i.e., IGF-I, IGF-II or insulin). Grey circle: cold ligand (i.e., IGF-I, IGF-II or insulin). a1 and d1:
ligand association and dissociation rate constants for the high-affinity site. a2 and d2: ligand association and dissociation rate constants for doubly liganded,
symmetrical receptor conformation. a3 and d3: association and dissociation rate constant for binding of a third insulin molecule (IR only, not applicable to
IGF-1R). b Plot for accelerated dissociation of a pre-bound tracer-labelled ligand by cold (unlabelled) ligand. The dissociation time was 20min. The
experimental data were as described previously (reproduced in Supplementary Table 4)18 and are shown as blue triangles for IGF-1 and red diamonds for
insulin, with the fit of the induced-fit model to these data shown as lines (IGF-I blue; insulin red)
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were integrated and scaled using the XDS package42; statistics are presented in
Table 1. The resolution limit was set at being the maximum at which the CC1/2
statistic43 remained significant at the P= 0.001 level of significance. For molecular
replacement, the diffraction data sets were further subjected to ellipsoidal trun-
cation and anisotropic scaling using the Diffraction Anisotropy Server44,45.
Structure determination and refinement. Molecular replacement (MR) structure
solution of the apo form of IGF-1RΔβ in complex with Fv 24–60 was undertaken
with PHASER46. Search objects for the L1-CR module and the L2 domain were
obtained directly from the structure of the IGF1R L1-CR-L2 fragment (PDB entry
1IGR25); search objects for IGF-1RΔβ FnIII-1 domain and the (FnIII-2)-(FnIII-3)
module were generated from their counterparts in the IRΔβ ectodomain structure
(PDB entry 3LOH); whereas a search object for Fv 24–60 was generated from the
structure of an anti-BclA scFv (PDB entry 3UMT; unpublished), modified by
replacing all non-identical residues with serine using the FFAS03 server47,48. The
MR search employed the anisotropy-corrected diffraction data set, as attempts
using the complete data set failed. The initial model was refined against all data to
3.0 Å resolution using PHENIX49 iterated with manual rebuilding using COOT50.
N-linked glycan residues were included where evident at Asn-X-Thr/Ser sequons.
Refinement included translation / libration / screw (TLS) parameters, using TLS
groups assigned by PHENIX. Within the refinement, the relative weighting of the
X-ray and stereochemistry terms and of the X-ray and atomic displacement
parameter terms were determined using the “automatic” protocol with PHENIX,
rather than the program default option. Ramachandran plot percentages are
favoured 92.3, allowed 6.6, outliers 1.1, rotamer outlier percentage is 0.2 and
MolProbity51 all-atom clash score is 6.6. Final refinement statistics for both
structures are in Table 1. Figures here and elsewhere were generated using
Chimera52.
Structure solution for the IGF-I-bound crystals of IGF-1RΔβ + Fv 24-60
employed PHASER (again employing an anisotropy-corrected data set), searching
with individual domains from the already refined Fv-complexed apo IGF-1RΔβ
structure. Electron density for the IGF-I ligand was readily visible, bound to the L1
domain and αCT helix in a fashion effectively identical to that seen in its complex
with the human insulin receptor domain L1 plus IGF-1R αCT (PDB entry 4XSS27),
allowing ready model building and structure refinement within PHENIX and
COOT as above, using all data to 3.26 Å resolution. N-linked glycan residues were
included where evident at Asn-X-Thr/Ser sequons. Ramachandran plot
percentages are favoured 92.2, allowed 7.3, outliers 0.5, rotamer outlier percentage
is 1.4 and MolProbity51 all-atom clash score is 6.3. Final refinement statistics are in
Table 1.
Comparison of IGF-1R and IR quaternary structure. The relative dispositions of
domains within IGF-1RΔβ compared to those of their counterparts in IRΔβ were
computed using ProSMART53, using a fragment length of 15 residues.
Mutant IGF-1R activation assays. Synthetic double-stranded complementary
DNA (cDNA) fragments (Supplementary Table 3) incorporating either His774Ala,
Ser788Ala, Asn789Ala, Phe790Ala, Phe792Ala or Phe790Ala/Phe792Ala (Inte-
grated DNA Technologies) were cloned into an existing pcDNA3.1 plasmid
incorporating the entire IGF-1R cDNA. Sequence-verified plasmids were tran-
siently transfected into R− cells (fibroblasts derived from IGF-1R knockout mice54,
a gift from Dr Renato Baserga) and after 48 h cells expressing the IGF-1R mutants
were stimulated with 100 nM IGF-I for 10 min. Cells were lysed36 in 20 mM
HEPES, 150 mM NaCl, 1.5 mM MgCl2, 10% glycerol, 1% Triton X-100, 1 mM
EGTA, pH 7.5 (lysis buffer) containing cOmplete protease inhibitor cocktail and
PhosSTOP (Sigma-Aldrich), 2 mM Na3VO4, 100 mM NaF for 1 h at 4 °C; lysates
were stored at −80 °C. Activation of the IGF-1R mutants was assessed by immu-
noblotting lysates with an antibody (#44–806G, Invitrogen; 1:2000 dilution, raised
in rabbit) specific for phosphorylated Tyr1158/Tyr1162/Tyr1163 (in the IGF-1R
kinase activation loop). Total receptor expression was measured by probing with an
IGF-1R antibody (3027S, Cell Signaling; 1:1000 dilution, raised in rabbit) and an
anti-tubulin antibody (Invitrogen; 1:1000 dilution, raised in mouse) was used as a
loading control. Anti-rabbit IR dye 680RD and anti-mouse IR dye 800CW (Licor;
1:50,000 dilution) were used as secondary antibodies. Quantitation of the blots was
achieved using the Image Studio Lite quantitation software (LI-COR Biosciences)
as follows. First, the IGF-1R expression levels were normalized to the tubulin
expression in each lane, as were the levels of Tyr1158/Tyr1162/Tyr1163 phos-
phorylation. The fold activation above basal was then calculated by comparing
levels of Tyr1158/Tyr1162/Tyr1163 phosphorylation in non-stimulated and sti-
mulated samples. Data represent n= 3 technical replicates and were analysed using
one-way analysis of variance within Prism 7.0 (GraphPad).
Mutant IGF-1R affinity assays. After 72 h of transfection of WT and mutant IGF-
IR into R− cells, cells were lysed with lysis buffer (20 mM HEPES, 150 mM NaCl,
1.5 mM MgCl2, 10% v/v glycerol, 1% v/v Triton X-100, 1 mM EGTA (pH 7.5)) for
1 h at 4 °C. Lysates were centrifuged for 10 min at 3500 rpm and then 100 μl was
added per well to a white Greiner Lumitrac 600 plate previously coated with anti-
IGF-1R antibody 24–3123 and blocked with 0.5% bovine serum albumin in TBST
(20 mM Tris, 150 mM NaCl, 0.05% v/v Tween-20). P6 cells (a gift from Dr Renato
Baserga) were used as a positive control for over-expression of the wild-type IGF-
IR55. Plates were incubated at 4 °C for 16 h.
Europium-labelled receptor-grade human IGF-I (Gropep Bioreagents;
Australia) was prepared as instructed by the manufacturer (DELFIA Eu-labelling
kit, Perkin Elmer). Approximately 3 × 106 fluorescent counts of europium-labelled
IGF-I were added to each well along with IGF-I competitor (0–300 nM) in
triplicate and incubated for 16 h at 4 °C. Wells were washed three times with TBST,
followed by addition of DELFIA enhancement solution (100 μl per well). After 10
min, time-resolved fluorescence was measured using 340 nm excitation and 612 nm
emission filters with a Victor X4 2030 Multilabel Reader (Perkin Elmer). IC50
values were calculated using Prism 7.0 (GraphPad) for curve-fitting of a one-site
competition model.
Modelling negative cooperativity of IGF-1R and IR. The experimental data for
negative cooperativity of IGF-1R and IR were those described previously18 and are
provided for completeness here in Supplementary Table 4 by permission of Pro-
fessor Pierre De Meyts. As indicated in the Discussion, the initial binding of ligand
to the “closed” form of receptor can be explained by an induced fit model or by
transient receptor opening, the latter effectively being described by the HO model18
upon reversal of the percentage of times that the receptor spends in its respective
open and closed conformations. The exact nature of this binding event is not
important for the modelling presented here, as its sequential components can be
grouped into a single reaction (Supplementary Figure 5a) that represents high-
affinity receptor binding (and receptor activation). Binding of a second ligand
would then lead to either an asymmetric or symmetric receptor conformation. Both
cases need to be considered. (i) In case of an asymmetric conformation, the second
ligand hypothetically binds to a partially open site 1 of the alternate pair of binding
sites, without it engaging site 2 (Supplementary Figure 5b). This interaction is
expected to have a lower affinity to that of an interaction engaging both sites. In
order for the negative cooperativity to occur, the asymmetric conformation is
presumed to transition between the two possible states in which the ligand initially
bound with high affinity disengages site 2 (leading to low affinity) and the ligand
initially bound with low affinity to site 1 alone engages both sites (leading to high
affinity) (Supplementary Figure 5b). This mechanism is formally identical to
negative cooperativity within HO model, and thus the HO formalism can be
applied (albeit with an alternative structural interpretation). (ii) In the case of a
symmetric conformation (Supplementary Figure 5c), the two sites have ligand
bound with identical affinity. This affinity is expected to be reduced compared to
that of the singly bound receptor, as otherwise we would have a receptor with two
high-affinity sites, contradicting binding data that demonstrate that there is only
one high-affinity site per holo-receptor18,38,56, unlike the soluble IR ectodomain
that has two equal lower-affinity sites57. Indeed, it is plausible that symmetrical
opening of the receptor domains to accommodate two ligands requires distortion
of the receptor structure in energetically costly fashion that reduces ligand affinity.
The binding of a third insulin molecule is proposed to account for the ascending
phase of accelerated dissociation for IR38. IGF-1R lacks this part of the curve and
thus, for simplicity, binding of the third ligand will be considered only in the case
of insulin binding to IR. Additional separation (“opening”) of the receptor domains
may be required to accommodate the third ligand (Supplementary Figure 5d),
presumably via an energetically unfavourable process that results in very low
affinity for that ligand. It is proposed that binding of the third ligand “locks” the
tracer in the bound state in the experiment for accelerated dissociation, and tracer
dissociation can only occur after the cold ligand dissociates38. Taking into account
the above described binding reactions, the model proposed here with the use of
doubly liganded, symmetrical receptor conformation leads to a compact binding
scheme of the ligand–receptor interaction (Supplementary Figure 5e). It should be
noted that this binding scheme is applicable only to the experimental conditions
described above. For example, receptor intermediaries with two or three hot ligand
molecules bound were excluded from the reaction scheme, since they would not be
formed in any significant quantities at 10 pM ligand concentration. Similarly,
intermediates with only cold ligand molecules bound were eliminated due to tracer
pre-binding. Endocytosis is, however, included, as even though the binding data
were derived from experiments performed at 16 °C, endocytosis at this temperature
cannot be totally excluded18. Thus, as within the HO model, it is assumed that
upon activation of inactive receptor intermediary, R000, the active intermediaries
such as Rh00, R0c0, Rhc0 or Rhcc (see Supplementary Figure 5e) are internalized with
an internalization rate constant kend. Upon internalization, it is assumed that ligand
dissociates instantly which leads to accumulation of hot ligand, Ligend, and inter-
nalized receptor, Rcyt, inside the cells. The internalized receptor, Rcyt, is recycled
back to the plasma membrane with an exocytosis rate constant, kex. The inter-
nalized ligand, Ligend, is recycled out of cells (either intact or degraded) with an
exocytosis rate constant, kex. The binding of two species of ligand (hot and cold) in
the presence of endo- and exocytosis and under conditions of no ligand depletion
can be described by a system of ordinary differential equations shown in Supple-
mentary Figure 6. The rate constants for endocytosis and exocytosis in IM9 cells
were taken from the HO model18. The initial values for a1 and d1 (high affinity)
site, a2 and d2 (low affinity symmetrical conformation) and a3 and d3 (describing
binding of the third insulin molecule) were also taken from the HO model18 and
manually optimized to achieve a fit to experimental data for accelerated dissocia-
tion at 20 min while keeping the high-affinity site constrained to Kd= 0.12 nM for
IGF-I and Kd= 0.2 nM for insulin and the low-affinity site to Kd= 4.3 nM in case
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of IGF-I and Kd= 6 nM in case of insulin. Simulations were performed using
Mathematica v11.0 (Wolfram). The optimized parameter values are shown in
Supplementary Table 5. No attempt was made to obtain a best fit of parameters or
to establish if the identified parameter set is unique; nevertheless, the identified set
of parameters leads to good agreement with experimental data (Fig. 8b).
Data availability. The coordinates of the structures determined here and their
associated structure factors have been deposited in the Protein Data Bank
(accession codes 5U8R and 5U8Q). Other data are available from the corre-
sponding author upon reasonable request.
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